This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Registration Open! Global Virtual Patient & Caregiver Educational Forum on October 10
We can’t come to your city for a live local meeting, so we’ve gathered the top CLL experts, wise patients, and others from across the country for a day packed full of CLL education and support on Saturday, October 10. Learn more and register here!
CLL Society’s Updated Official Statement Concerning CLL Patients Working and Traveling During the COVID-19 Pandemic
As the COVID-19 pandemic stretches on, we have updated our official statement concerning working and traveling for people with CLL that you can download for your own reference and to share with the appropriate people in your life including HR, co-workers, extended family and friends.
Dr. Koffman’s ASCO 2020 “Top 12 Picks” Continued with #2:
#2 At virtual ASCO 2020, Dr. John Byrd led a group of researchers to report the latest from the first phase 2 study of acalabrutinib, ACE-CL-001 (NCT02029443), a next-generation BTK inhibitor, which is now approved for CLL patients, both treatment-naïve as well as those with relapsed/refractory disease.
ASH 2019, Dr. John Pagel interviews Dr. Sameer Parikh regarding a clinical trial out of all locations of the Mayo Clinic investigating the potential benefit of early intervention of high-risk CLL and SLL patients, as determined by the Prognostic CLL International Prognostic Index (IPI), with treatment regimens of either acalabrutinib or acalabrutinib + obinituzumab for a fixed duration of 2 years.
Upcoming CURE Webinar on August 27
Terry Evans, 20-year CLL survivor and CLL Society’s Director of Support Groups, joins panelists Dr. Erlene Seymour and Dr. Hun Ju Lee in CURE’s Educated Patient CLL Webinar on August 27, where discussion will focus on BTK inhibitors, oral vs. infusion treatment options, shared decision-making and other topics of importance to CLL patients and their caregivers. Learn more and register here.
Upcoming Webinar: Expert Perspectives on Incorporating BTK Inhibitors into the Treatment Plan for Patients with CLL
On September 3 at 10 AM PT / 1 PM ET join Dr. Parameswaran Venugopal from Rush University Medical Center in Chicago, IL and Bruce Wright, a Patient Advisor and Patient Educator for the CLL Society to discuss the clinical use of BTK inhibitors for the treatment of their CLL and equip patients with the appropriate knowledge to make informed decisions with their care providers. Bruce is a US military veteran who will speak to some of the challenges that are specific to veterans seeking treatment, as well as how patients and caregivers can increase their knowledge about CLL and become more involved in their treatment decisions. Learn more and register here.
Instant Replay! CLL Society’s Archived Webinar “MRD: What Should It Mean to Me?
In this August 14th CLL Society webinar, CLL expert Dr. Anthony Mato and moderator Dr. Brian Koffman discussed the latest information on MRD testing and answered audience questions. Watch the recorded webinar here.
Archived Webinar from Cancer Coach Live “What You Need to Know about BTK Inhibitors as Treatment for Your/Your Loved One’s CLL”
Now available on-demand, the August 10 Cancer Coach Live webinar, featuring CLL expert Dr. Matthew Davids, Associate Professor of Medicine Harvard Medical School, Nurse Practitioner Josie Montegaard, and CLL patient, frequent patient panelist, and CLL Society Tribune contributor, Doreen Zetterlund, promoting meaningful and productive dialog between patients and HCPs as relates to CLL treatment regimens incorporating BTK inhibitors. Watch the recorded webinar here.
Archived Webinar from Lymphoma Australia’s Virtual Conference
Our own Dr. Brian Koffman joined Dr. Matthew Davids from Dana Farber, Dr. Jason Butler from Brisbane, AU, and patient Deb Sims from Melbourne on August 17 to discuss CLL. Watch the recorded webinar here.
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
The CLL Society is invested in your long life.
Please invest in the long life of the CLL Society by investing in our work.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.